

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 02139.000029-L
INTERNATIONAL APPLICATION NO. PCT/JP00/05542	INTERNATIONAL FILING DATE 18 August 2000	U.S. APPLICATION NO. (If known, see 37 C.F.R.1.5) <b>10/049268</b>
PRIORITY DATE CLAIMED 18 August 1999		
TITLE OF INVENTION HAIR-GROWING AGENT		
APPLICANT(S) FOR DO/EO/US Tomoya Takahashi, et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li><input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li><input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li><input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input type="checkbox"/> have been transmitted by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 into English (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li><input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 into English (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 1 to 20 below concern other document(s) or information included:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input checked="" type="checkbox"/> A FIRST preliminary amendment.</li> <li><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li><input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li><input checked="" type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li><input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li><input checked="" type="checkbox"/> Other items or information: Application Data Sheet; Verification of Translation; Form PCT/RO/101; Form PCT/ISA/210; Form PCT/IB/301; Form PCT/IB/304; Form PCT/IB/308.</li> </ol>		

21.  The following fees are submitted:

## Basic National Fee (37 CFR 1.492(a)(1)-(5):

Search Report has been prepared by the EP or JPO ..... \$890.00

International preliminary examination fee paid to USPTO

(37 CFR 1.492(a)(1)) ..... \$710.00

No international preliminary examination fee paid to USPTO (37 CFR 1.492

(a)(1)) but international search fee paid to USPTO (37 CFR 1.492(a)(2)) ..... \$740.00

Neither international preliminary examination fee (37 CFR 1.492(a)(1))

nor international search fee (37 CFR 1.492(a)(2)) paid to USPTO ..... \$1,040.00

International preliminary examination fee paid to USPTO (37 CFR 1.492

(a)(4)) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims Number Filed Number Extra Rate

Total Claims 110 - 20 = 90 X \$18.00 \$1620.00

Independent Claims 9 - 3 = 6 X \$84.00 \$504.00

Multiple dependent claim(s) (if applicable) + \$280.00 \$280.00

TOTAL OF ABOVE CALCULATIONS = \$3294.00

 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. + \$

SUBTOTAL = \$3294.00

Processing fee of \$130.00 for furnishing the English translation later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE = \$3294.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$40.00

TOTAL FEES ENCLOSED = \$3334.00

Amount to be:

refunded \$

charged \$

- A check in the amount of \$3334.00 to cover the above fees is enclosed.
- Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1205. A duplicate copy of this sheet is enclosed.
- Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

SIGNATURE

Lawrence S. Perry

NAME

31.865

REGISTRATION NUMBER

02139.000029

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

TOMOYA TAKAHASHI, ET AL.

Application No.: Not Yet Assigned

(National Phase of PCT Application No.  
PCT/JP00/05542 filed August 18, 2000)

Filed: Currently herewith

For: HAIR-GROWING AGENT

)  
:  
Examiner: Not Yet Assigned  
)  
:  
Group Art Unit: Not Yet Assigned  
)  
:  
)  
:  
February 8, 2002

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to action on the merits, please amend the above-identified application as

follows:

IN THE SPECIFICATION:

Please substitute the paragraph at page 7, lines 3-4, with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

(20) The hair-growing agent according to any of the above (8) to (19), which does not substantially comprise minoxidil.

Please substitute the paragraph starting at page 8, line 14 and ending at page 9, line 23 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

The lysophosphatidic acids to be used in the present invention may be any lysophosphatidic acids. The phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms to be used in the present invention include all such phosphatidic acids. The straight-chain fatty acid residues having an even number of carbon atoms include those having 2 to 24, preferably 8 to 18 carbon atoms, such as ethanoyl, butanoyl, hexanoyl, octanoyl, decanoyl, dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl, eicosanoyl, docosanoyl, tetracosanoyl, 2-butenoyl, 3-butenoyl, 3-hexenoyl, 5-hexenoyl, hexadienoyl, octenoyl, decenoyl, dodecenoyl, tetradecenoyl, hexadecenoyl, octadecenoyl, butynoyl, hexynoyl, octynoyl, decynoyl, dodecynoyl, tetradecynoyl, hexadecynoyl, octadecynoyl and tetradec-4-en-8-ynoyl. Of the above lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms, preferred are compounds represented by formula (I). Examples of the lysophosphatidic acids are monoacetyl lysophosphatidic acid, monopropionyl lysophosphatidic acid, monobutanoyl lysophosphatidic acid, monopentanoyl lysophosphatidic acid, monohexanoyl lysophosphatidic acid, monoheptanoyl lysophosphatidic acid, monooctanoyl lysophosphatidic acid, monononanoyl lysophosphatidic acid, monodecanoyl lysophosphatidic acid, monoundecanoyl lysophosphatidic acid, monolauroyl lysophosphatidic acid, monotridecanoyl lysophosphatidic acid, monomyristoyl lysophosphatidic acid, monopentadecanoyl lysophosphatidic acid, monopalmitoyl lysophosphatidic acid, monoheptadecanoyl lysophosphatidic acid, monostearoyl lysophosphatidic acid and monooleoyl

lysophosphatidic acid. Examples of the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are dioleoyl phosphatidic acid, dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, dilauroyl phosphatidic acid, dioctanoyl phosphatidic acid, didecanoyl phosphatidic acid, distearoyl phosphatidic acid, arachidonoylstearyl phosphatidic acid, 1-oleoyl-2-acetyl phosphatidic acid, 1-lauroyl-2-acetyl phosphatidic acid, 1-myristoyl-2-acetyl phosphatidic acid, 1-palmitoyl-2-acetyl phosphatidic acid, 1-stearoyl-2-acetyl phosphatidic acid and 1-palmitoleoyl-2-acetyl phosphatidic acid.

Please substitute the paragraph at page 14, lines 24-33 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Grape-derived proanthocyanidin can be extracted and purified according to the method described in *Acta Dermato Venereologica*, 78, 428-432 (1998) or a similar method. Procyanidin B-1 [epicatechin-(4 $\beta$ →8)-catechin], procyanidin B-2 [epicatechin-(4 $\beta$ →8)-epicatechin], procyanidin B-3 [catechin-(4 $\alpha$ →8)-catechin] and procyanidin C-1 [epicatechin-(4 $\beta$ →8)-epicatechin-(4 $\beta$ →8)-epicatechin] can be extracted and purified according to the method described in *The Journal of Investigative Dermatology*, 112, 310-316 (1999) or a similar method.

Please substitute the paragraph at page 19, lines 9-19 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Examples of the surfactants are polyoxyethylene (60) hardened castor oil, polyoxyethylene (8) oleyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (10)

monooleate, sorbitan monostearate, polyoxyethylene (30) glyceryl monostearate, polyoxyethylene (20) sorbitan monooleate, sucrose fatty acid esters, hexaglycerin monooleate, hexaglycerin monolaurate, polyoxyethylene reduced lanolin, polyoxyethylene (20) lanolin alcohol, polyoxyethylene (25) glyceryl pyroglutamate isostearate, and N-acetylglutamine isostearyl ester.

Please substitute the paragraph at page 21, lines 34-36 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Grape-derived proanthocyanidin was produced according to the method

described in *Acta Dermato Venereologica*, 78, 428-432 (1998).

Please substitute the paragraph at page 22, lines 18-20 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Procyanidin B-2 was produced according to the method described in *The*

*Journal of Investigative Dermatology*, 112, 310-316 (1999).

Please substitute the paragraph at page 23, lines 1-3 have with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Procyanidin C-1 was produced according to the method described in *The*

*Journal of Investigative Dermatology*, 112, 310-316 (1999).

Please substitute Table 1 at page 27 with the following replacement Table 1. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Table 1

<u>Test Compound</u>	PKC-IC <sub>50</sub> μmol/l	PKA-IC <sub>50</sub> μmol/l	PKA-IC <sub>50</sub> / μmol/l
Calphostin C	0.05	>50	>1000
Hexadecyl- phosphocholine	94	>1000	>10.6
Palmitoyl-DL- carnitine	230	>1000	>4.3
Polymyxin B	2.6	>1000	>384

Please substitute the paragraph starting at page 31, line 12 and ending at page 32, line 3 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Nine-weeks-old male C3H/HeSlc mice whose hair cycle was in the telogen were divided into groups each consisting of 4 or 5 mice. Hair on the back of each mouse was shaven using electric hair clippers and an electric shaver. Then, the compositions prepared in Examples 1-13 were applied on the shaven part in an amount of 200 μl once per day. To the mice of control groups were applied compositions 2 and 16 respectively in the same manner.

Please substitute the paragraph starting at page 32, line 14 and ending at page 33, line 11 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Table 3 (1) Hair growth-promoting effect of lysophosphatidic acid on mouse

Composition	Rate of increased hair-grown area (%)
2 (Control group)	0
1	35
3	60
4	45
5	64
6	51
7	67
8	57
9	68
10	60
11	73
12	63
13	60
14	45

Table 3 (2) Hair growth-promoting effect of phosphatidic acids on mouse

Composition	Rate of increased hair-grown area (%)
16 (Control group)	0
15	44
17	51
18	40
19	55
20	44
21	58
22	46
23	52
24	39
25	41


As shown in Table 3, the hair-growing agents comprising lysophosphatidic acid or phosphatidic acid of the present invention exhibited a significant hair growth-promoting effect on mouse. The hair growth-promoting effect of proanthocyanidin, protein kinase C-specific inhibitors and tocopherol on hair follicles was reinforced by using them together with the

lysophosphatidic acid.

IN THE CLAIMS:


Please amend Claims 5-7, 11, 13, 14 and 16-22 and add new claims 23-49 to read as follows. A marked-up copy of these claims, showing the changes made thereto, is attached.

5. (Amended) The hair-growing agent according to Claim 1 or 2, wherein the lysophosphatidic acids are compounds represented by formula (I):




(wherein R<sup>1</sup> represents alkyl, alkenyl or alkynyl).

6. (Amended) The hair-growing agent according to Claim 1 or 2, wherein the lysophosphatidic acids are compounds represented by formula (II):



(wherein R<sup>2</sup> has the same significance as the above R<sup>1</sup>).

7. (Amended) The hair-growing agent according to Claim 1 or 2, wherein the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are compounds represented by formula (III):



(wherein  $\text{R}^3$  and  $\text{R}^4$ , which

may be the same or different, each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

11. (Amended) The hair-growing agent according to Claim 9, further comprising a protein kinase C-specific inhibitor or a pharmaceutically acceptable salt thereof.


13. (Amended) The hair-growing agent according to Claim 8 or 12, wherein the protein kinase C-specific inhibitor is one or more members selected from the group consisting of calphostin C, hexadecylphosphocholine, palmitoyl-DL-carnitine and polymyxin B.

14. (Amended) The hair-growing agent according to Claims 9 or 12, further comprising tocopherol.

16. (Amended) The hair-growing agent according to Claim 8 or 15, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.


17. (Amended) The hair-growing agent according to any of Claim 8, 9, 11, 12, 15, 30, 33, 36, 39 or 42, wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

18. (Amended) The hair-growing agent according to Claim 17, wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are compounds represented by formula (III):




(wherein R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

19. (Amended) The hair-growing agent according to any of Claims 8, 9, 11, 12, 15, 30, 33, 36, 39 or 42 wherein the lysophosphatidic acids are compounds represented by formula (I):



(wherein R<sup>1</sup> represents alkyl, alkenyl or alkynyl), or compounds represented by formula (II):



(wherein R<sup>2</sup> has the same significance as the above R<sup>1</sup>).


20. (Amended) The hair-growing agent according to any of Claims 8, 9, 12 or

15, which does not substantially comprise minoxidil.

21. (Amended) The hair-growing agent according to Claim 20, wherein the content of one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids is 0.01 to 5.0%.


22. (Amended) The hair-growing agent according to Claim 20, wherein the content of one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids is 0.01 to 1.0%.

23. (New) The hair-growing agent according to Claim 3, wherein the lysophosphatidic acids are compounds represented by formula (I):




(wherein  $\text{R}^1$  represents alkyl, alkenyl or alkynyl).

24. (New) The hair-growing agent according to Claim 4, wherein the lysophosphatidic acids are compounds represented by formula (I):




(wherein  $\text{R}^1$  represents alkyl, alkenyl or alkynyl).

25. (New) The hair-growing agent according to Claim 3, wherein the lysophosphatidic acids are compounds represented by formula (II):




(wherein  $\text{R}^2$  has the same significance as the above  $\text{R}^1$ ).

26. (New) The hair-growing agent according to Claim 4, wherein the lysophosphatidic acids are compounds represented by formula (II):




(wherein  $\text{R}^2$  has the same significance as the above  $\text{R}^1$ ).

27. (New) The hair-growing agent according to Claim 3, wherein the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are compounds represented by formula (III):



(wherein  $\text{R}^3$  and  $\text{R}^4$ , which may be the same or different, each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

28. (New) The hair-growing agent according to Claim 4, wherein the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are compounds represented by formula (III):



(wherein  $\text{R}^3$  and  $\text{R}^4$ , which may be the same or different, each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

29. (New) The hair-growing agent according to Claim 10, further comprising a protein kinase C-specific inhibitor or a pharmaceutically acceptable salt thereof.

30. (New) The hair-growing agent according to Claim 11, wherein the protein kinase C-specific inhibitor is one or more members selected from the group consisting of calphostin C, hexadecylphosphocholine, palmitoyl-DL-carnitine and polymyxin B.

31. (New) The hair-growing agent according to Claim 29, wherein the protein kinase C-specific inhibitor is one or more members selected from the group consisting of calphostin C, hexadecylphosphocholine, palmitoyl-DL-carnitine and polymyxin B.

32. (New) The hair-growing agent according to Claim 10, further comprising tocopherol.

33. (New) The hair-growing agent according to Claim 11, further comprising tocopherol.

34. (New) The hair-growing agent according to Claim 29, further comprising tocopherol.

35. (New) The hair-growing agent according to Claim 13, further comprising tocopherol.

36. (New) The hair-growing agent according to Claim 30, further comprising

tocopherol.

37. (New) The hair-growing agent according to Claim 31, further comprising tocopherol.

38. (New) The hair-growing agent according to Claim 32, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

39. (New) The hair-growing agent according to Claim 33, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

40. (New) The hair-growing agent according to Claim 34, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

41. (New) The hair-growing agent according to Claim 35, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

42. (New) The hair-growing agent according to Claim 36, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

43. (New) The hair-growing agent according to Claim 37, wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

44. (New) A method for hair growth in a mammal, which comprises applying to the skin of said mammal one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

45. (New) A method for stimulating hair growth in a mammal, which comprises applying to the skin of said mammal one or more member selected from the group consisting of lysophosphatidic acids and phosphatidic acids, and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific inhibitors or pharmaceutically acceptable salts thereof, and tocopherol.

46. (New) The method according to Claim 45, wherein the phosphatidic acids are those wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

47. (New) A method of preparing a hair growing composition, comprising selecting one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms; and admixing said member with an acceptable diluent.

48. (New) A method of preparing a hair growing composition, comprising selecting

one or more members selected from the group consisting of lyzophosphatidic acids and phosphatidic acids, and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific inhibitors or pharmaceutically acceptable salts thereof, and tocopherol; and admixing said member with an acceptable diluent.

49. (New) The method according to Claim 48, wherein the phosphatidic acids are those wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

REMARKS

The claims have been amended, and claims 23-49 have been added, to correct their dependency in conformity with accepted U.S. practice. Claims 44-49 are added in order to more specifically recite various preferred embodiments of the present invention and the specification has been amended in order to correct various typographical errors. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respeetfully submitted,

Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200


### LSP\ac

NY MAIN 236547 v1

Application No: (National Phase of PCT Application No. PCT/JP00/05542 filed August 18, 2000)  
Attorney Docket No. 02139.000029


VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

5. (Amended) The hair-growing agent according to [any of] Claim[s] 1 [to 4] or 2, wherein the lysophosphatidic acids are compounds represented by formula (I):



(wherein  $\text{R}^1$  represents alkyl, alkenyl or alkynyl).


6. (Amended) The hair-growing agent according to [any of] Claim[s] 1 [to 4] or 2, wherein the lysophosphatidic acids are compounds represented by formula (II):



(wherein  $\text{R}^2$  has the same significance as the above  $\text{R}^1$ ).

7. (Amended) The hair-growing agent according to [any of] Claim[s] 1 [to 4]

or 2, wherein the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are compounds represented by formula (III):



(wherein R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

11. (Amended) The hair-growing agent according to Claim 9 [or 10], further

comprising a protein kinase C-specific inhibitor or a pharmaceutically acceptable salt thereof.

13. (Amended) The hair-growing agent according to Claim 8[, 11] or 12, wherein the protein kinase C-specific inhibitor is one or more members selected from the group

consisting of calphostin C, hexadecylphosphocholine, palmitoyl-DL-carnitine and polymyxin B.

14. (Amended) The hair-growing agent according to any of Claims 9 [to 13] or

12, further comprising tocopherol.

16. (Amended) The hair-growing agent according to Claim 8[, 14] or 15,

wherein the tocopherol is one or more members selected from the group consisting of dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol nicotinate.

17. (Amended) The hair-growing agent according to any of Claim[s 8 to 16] 8, 9,


11, 12, 15, 30, 33, 36, 39 or 42, wherein the [phosphatidic acids are the phosphatidic acids

according to Claim 1] fatty acid residue moiety consists only of straight-chain fatty acid residues  
having an even number of carbon atoms.

18. (Amended) The hair-growing agent according to Claim 17, wherein the

[phosphatidic acids are the phosphatidic acids according to Claim 7] fatty acid residue moiety


consists only of straight-chain fatty acid residues having an even number of carbon atoms are  
compounds represented by formula (III):




(wherein R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represents straight-chain alkyl  
having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon  
atoms, or straight-chain alkynyl having an odd number of carbon atoms).

ENTRIES-SEARCHED

19. (Amended) The hair-growing agent according to any of Claims [8 to 16] 8, 9, 11, 12, 15, 30, 33, 36, 39 or 42 wherein the lysophosphatidic acids are [the lysophosphatidic acids according to Claim 5 or 6] compounds represented by formula (I):



(wherein R<sup>1</sup> represents alkyl, alkenyl or alkynyl, or compounds represented by formula (II):



(wherein R<sup>2</sup> has the same significance as the above R<sup>1</sup>).

2002139.000029

20. (Amended) The hair-growing agent according to any of Claims 8 [to 19], 9,

12 or 15, which does not substantially comprise minoxidil.

21. (Amended) The hair-growing agent according to [any of] Claim[s 8 to] 20,

wherein the content of one or more members selected from the group consisting of  
lysophosphatidic acids and phosphatidic acids is 0.01 to 5.0%.

22. (Amended) The hair-growing agent according to [any of] Claim[s 8 to] 20,

wherein the content of one or more members selected from the group consisting of  
lysophosphatidic acids and phosphatidic acids is 0.01 to 1.0%.

Application No: (National Phase of PCT Application No. PCT/JP00/05542 filed August 18, 2000)  
Attorney Docket No. 02139.000029

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO SPECIFICATION

The paragraph at page 7, lines 3-4 have been amended as follows:

(20) The hair-growing agent according to any of the above (8) to (19), which does not substantially comprise minoxidil.

The paragraph starting at page 8, line 14 and ending at page 9, line 23 has been amended as follows:

The lysophosphatidic acids to be used in the present invention may be any lysophosphatidic acids. The phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms to be used in the present invention include all such phosphatidic acids. The straight-chain fatty acid residues having an even number of carbon atoms [of the above fatty acid residues] include[s] those having 2 to 24, preferably 8 to 18 carbon atoms, such as ethanoyl, butanoyl, hexanoyl, octanoyl, decanoyl, dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl, eicosanoyl, docosanoyl, tetracosanoyl, 2-butenoyl, 3-butenoyl, 3-hexenoyl, 5-hexenoyl, hexadienoyl, octenoyl, decenoyl, dodecenoyl, tetradecenoyl, hexadecenoyl, octadecenoyl, butynoyl, hexynoyl, octynoyl, decynoyl,

dodecynoyl, tetradecynoyl, hexadecynoyl, octadecynoyl and tetradec-4-en-8-ynoyl. Of the above lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms, preferred are compounds represented by formula (I). Examples of the lysophosphatidic acids are monoacetyl lysophosphatidic acid, monopropionyl lysophosphatidic acid, monobutanoyl lysophosphatidic acid, monopentanoyl lysophosphatidic acid, monohexanoyl lysophosphatidic acid, monoheptanoyl lysophosphatidic acid, monoheptanoyl lysophosphatidic acid, monooctanoyl lysophosphatidic acid, monononanoyl lysophosphatidic acid, monodecanoyl lysophosphatidic acid, monoundecanoyl lysophosphatidic acid, monolauroyl lysophosphatidic acid, monotridecanoyl lysophosphatidic acid, monomyristoyl lysophosphatidic acid, monopentadecanoyl lysophosphatidic acid, monopalmitoyl lysophosphatidic acid, monoheptadecanoyl lysophosphatidic acid, monostearoyl lysophosphatidic acid and monooleoyl lysophosphatidic acid. Examples of the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are dioleoyl phosphatidic acid, dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, dilauroyl phosphatidic acid, dioctanoyl phosphatidic acid, didecanoyl phosphatidic acid, distearoyl phosphatidic acid, arachidonoylstearyl phosphatidic

acid, 1-oleoyl-2-acetyl phosphatidic acid, 1-lauroyl-2-acetyl phosphatidic acid, 1-myristoyl-2-acetyl phosphatidic acid, 1-palmitoyl-2-acetyl phosphatidic acid, 1-stearoyl-2-acetyl phosphatidic acid and 1-palmitoleoyl-2-acetyl phosphatidic acid.

The paragraph at page 14, lines 24-33 have been amended as follows:

Grape-derived proanthocyanidin can be extracted and purified according to the method

described in *Acta Dermato Venereologica*, 78, 428-432 (1998) or a similar method. Procyanidin B-1 [epicatechin-(4 $\beta$ →8)-catechin], procyanidin B-2 [epicatechin-(4 $\beta$ →8)-epicatechin], procyanidin B-3 [catechin-([4 $\beta$ ] 4 $\alpha$ →8)-catechin] and procyanidin C-1 [epicatechin-(4 $\beta$ →8)-epicatechin-(4 $\beta$ →8)-epicatechin] can be extracted and purified according to the method described in *The Journal of Investigative Dermatology*, 112, 310-316 (1999) or a similar method.

The paragraph at page 19, lines 9-19 have been amended as follows:

Examples of the surfactants are polyoxyethylene (60) hardened castor oil, polyoxyethylene (8) oleyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (10) monooleate, [polyoxyethylene (30) glyceryl monostearate], sorbitan monostearate,

polyoxyethylene (30) glyceryl monostearate, polyoxyethylene (20) sorbitan monooleate, sucrose fatty acid esters, hexaglycerin monooleate, hexaglycerin monolaurate, polyoxyethylene reduced lanolin, polyoxyethylene (20) lanolin alcohol, polyoxyethylene (25) glyceryl pyroglutamate isostearate, and N-acetylglutamine isostearyl ester.

The paragraph at page 21, lines 34-36 have been amended as follows:

Grape-derived proanthocyanidin was produced according to the method described in Acta Dermato Venereologica, 78, 428-432 (1998) [or a similar method].

The paragraph at page 22, lines 18-20 have been amended as follows:

Procyanidin B-2 was produced according to the method described in The Journal of Investigative Dermatology, 112, 310-316 (1999) [or a similar method].

The paragraph at page 23, lines 1-3 have been amended as follows:

Procyanidin C-1 was produced according to the method described in The Journal of Investigative Dermatology, 112, 310-316 (1999) [or a similar method].

Table 1 at page 27 has been amended as follows:

Table 1

Test Compound	PKC-IC <sub>50</sub> [(μM)] $\mu$ mol/l	PKA-IC <sub>50</sub> [(μM)] $\mu$ mol/l	PKA-IC <sub>50</sub> / [PKC-IC <sub>50</sub> ] $\mu$ mol/l
Calphostin C	0.05	>50	>1000
Hexadecyl- phosphocholine	94	>1000	>10.6
Palmitoyl-DL- carnitine	230	>1000	>4.3
Polymyxin B	2.6	>1000	>384

The paragraph starting at page 31, line 12 and ending at page 32, line 3 has been amended as follows:

Nine-weeks-old male C3H/HeSlc mice whose hair cycle was in the telogen were divided into groups each consisting of 4 or 5 mice. Hair on the back of each mouse was shaven using electric hair clippers and an electric shaver. Then, the compositions prepared in Examples 1-[14]13 were applied on the shaven part in an amount of 200  $\mu$ l once per day. To the mice of control groups were applied compositions 2 and 16 respectively in the same manner.

The paragraph starting at page 32, line 14 and ending at page 33, line 11 has been amended as follows:

Table 3 (1) [Growth] Hair growth-promoting effect of lysophosphatidic acid on mouse [hair follicle]

Composition	Rate of increased hair-grown area (%)
2 (Control group)	0
1	35
3	60
4	45
5	64
6	51
7	67
8	57
9	68
10	60
11	73
12	63
13	60
14	45

Table 3 (2) [Growth] Hair growth-promoting effect of phosphatidic acids  
on mouse [hair follicle]

Composition	Rate of increased hair-grown area (%)
16 (Control group)	0
15	44
17	51
18	40
19	55
20	44
21	58
22	46
23	52
24	39
25	41

As shown in Table 3, the hair-growing agents comprising lysophosphatidic acid

or phosphatidic acid of the present invention exhibited a significant hair growth-promoting effect

on mouse [hair follicles]. The hair growth-promoting effect of proanthocyanidin, protein kinase

C-specific inhibitors and tocopherol on hair follicles was reinforced by using them together with

the lysophosphatidic acid.

SPECIFICATION  
HAIR-GROWING AGENTTechnical Field

5 The present invention relates to a hair-growing agent comprising a lysophosphatidic acid or a phosphatidic acid as an active ingredient, which has an excellent scalp hair-growing effect.

Background Art

In spite of studies on lots of substances aimed at the development of therapeutic agents for androgenetic alopecia, a substance which can be used as a safe and effective therapeutic agent for androgenetic alopecia has not been discovered yet. Minoxidil, which has been used as a therapeutic agent for hypertension, was found to bring about hypertrichosis as its side effect [British Journal of Dermatology, 101, 593-595 (1979)]. At present, it is used as a therapeutic agent for androgenetic alopecia, but is not completely satisfactory in respect of effectiveness, safety and side effect.

On the other hand, a large number of plant extracts have been conventionally used for the treatment of androgenetic alopecia. For example, an extract of *Swertia japonica* Makino, which is believed to have the activity to accelerate blood flow in capillary, is employed as a hair-growing agent [Tokushima Journal of Experimental Medicine, 2, 37-59 (1962)]. However, its effect is not sufficient.

An example of a known hair-growing agent comprising a lysophosphatidic acid or a phosphatidic acid is a minoxidil liposome preparation containing a lysophosphatidic acid or a phosphatidic acid as a liposome constitutive vehicle (US 5030442). Also known are a hair-nourishing agent comprising a phosphatidic acid having a fatty acid residue having a carbon chain with odd carbon number (Japanese Published Examined Patent Application No.

41363/88) and a cell activator comprising a phosphatidic acid having branched-chain fatty acid residues (Japanese Published Unexamined Patent Application No. 7205/86).

However, there has not been known a hair-growing agent comprising a lysophosphatidic acid as an active ingredient or a hair-growing agent comprising a phosphatidic acid wherein all fatty acid residues are straight-chain fatty acid residues having an even number of carbon atoms. A mixture of some phospholipids including a phosphatidic acid is known to have apoptosis-inhibiting activity (WO 97/09989). Also known is a hair-growing agent comprising a phospholipid mixture (DE3222016 A1, DE4113346 A1).

WO 96/00561 describes a hair-growing agent comprising proanthocyanidin. Japanese Published Unexamined Patent Application No. 315947/97 describes a hair-growing agent comprising a protein kinase C (PKC)-specific inhibitor. It is known that tocopherol has hair-growing activity ["Ke no Igaku" (Medical Science of Hair), p. 283, Bunkodo (1987); Hair Science, p. 80, Japan Hair Science Association (1986)]. However, there is no report on a hair-growing agent comprising a phosphatidic acid and proanthocyanidin as active ingredients, a hair-growing agent comprising a phosphatidic acid and a protein kinase C-specific inhibitor as active ingredients, or a hair-growing agent comprising a phosphatidic acid and tocopherol as active ingredients.

#### Disclosure of the Invention

The present inventors have searched for a substance which exhibits hair-growing activity by external application. As a result of a series of studies, they have found a strong hair-growing activity in a lysophosphatidic acid and in a phosphatidic acid wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms. They have also found a strong hair-growing

NOTIFICATION

activity in a composition comprising, as active ingredients, lysophosphatidic acid or phosphatidic acid, and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific inhibitors or pharmaceutically acceptable salts thereof, and tocopherol.

The present invention relates to the following (1) to (22).

10 (1) A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.


15 (2) The hair-growing agent according to the above (1), which does not substantially comprise minoxidil.

20 (3) The hair-growing agent according to the above (1) or (2), wherein the content of one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms is 0.01 to 5.0%.

25 (4) The hair-growing agent according to the above (1) or (2), wherein the content of one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms is 0.01 to 1.0%.

30 (5) The hair-growing agent according to any of the above


(1) to (4), wherein the lysophosphatidic acids are compounds represented by formula (I):



5

(wherein  $\text{R}^1$  represents alkyl, alkenyl or alkynyl).

(6) The hair-growing agent according to any of the above (1) to (4), wherein the lysophosphatidic acids are compounds represented by formula (II):



10


10

(wherein  $\text{R}^2$  has the same significance as the above  $\text{R}^1$ ).

15

20

(7) The hair-growing agent according to any of the above (1) to (4), wherein the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are compounds represented by formula (III):



25

(wherein  $R^3$  and  $R^4$ , which may be the same or different, each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

- (8) A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids, and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific inhibitors or pharmaceutically acceptable salts thereof, and tocopherol.
- (9) A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids, and proanthocyanidin.
- (10) The hair-growing agent according to the above (8) or (9), wherein the proanthocyanidin is one or more members selected from the group consisting of procyanidin B-1, procyanidin B-2, procyanidin B-3 and procyanidin C-1.
- (11) The hair-growing agent according to the above (9) or (10), further comprising a protein kinase C-specific inhibitor or a pharmaceutically acceptable salt thereof.
- (12) A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids, and a protein kinase C-specific

inhibitor or a pharmaceutically acceptable salt thereof.

5 (13) The hair-growing agent according to the above (8),  
inhibitor is one or more members selected from the  
group consisting of calphostin C,  
hexadecylphosphocholine, palmitoyl-DL-carnitine and  
polymyxin B.

10 (14) The hair-growing agent according to any of the above  
(9) to (13), further comprising tocopherol.

15 (15) A hair-growing agent comprising, as active  
ingredients, one or more members selected from the  
group consisting of lysophosphatidic acids and  
phosphatidic acids, and tocopherol.

20 (16) The hair-growing agent according to the above (8),  
(14) or (15), wherein the tocopherol is one or more  
members selected from the group consisting of dl- $\alpha$ -  
tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate,  
d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol  
nicotinate.

25 (17) The hair-growing agent according to any of the above  
(8) to (16), wherein the phosphatidic acids are the  
phosphatidic acids according to the above (1).

30 (18) The hair-growing agent according to the above (17),  
wherein the phosphatidic acids are the phosphatidic  
acids according to the above (7).

35 (19) The hair-growing agent according to any of the above  
(8) to (16), wherein the lysophosphatidic acids are  
the lysophosphatidic acids according to the above (5)

or (6).

(20) The hair-growing agent according to the above (8) to (19), which does not substantially comprise minoxidil.

5 (21) The hair-growing agent according to any of the above (8) to (20), wherein the content of one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids is 0.01 to 5.0%.

10 (22) The hair-growing agent according to any of the above (8) to (20), wherein the content of one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids is 0.01 to 1.0%.

15 In the definition of each group in formula (I), the alkyl includes straight-chain or branched alkyl groups having 1 to 23, preferably 7 to 17 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl. The 20 alkenyl includes straight-chain or branched alkenyl groups having 2 to 23, preferably 7 to 17 carbon atoms, such as vinyl, allyl, butenyl, pentenyl, hexenyl, pentadienyl and hexadienyl. The alkynyl includes straight-chain or branched alkynyl groups having 2 to 23, preferably 7 to 17 carbon atoms, such as ethynyl, propynyl, butynyl, pentynyl and hexynyl.

25 The straight-chain alkyl having an odd number of carbon atoms includes those having 1 to 23, preferably 7 to 17 carbon atoms, such as methyl, propyl, pentyl, heptyl, nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, 30 nonadecyl, heneicosanyl and tricosanyl. The straight-

chain alkenyl having an odd number of carbon atoms includes those having 3 to 23, preferably 7 to 17 carbon atoms, such as allyl, 1-propenyl, 2-pentenyl, 4-pentenyl, pentadienyl, heptenyl, nonenyl, undecenyl, tridecenyl, 5 pentadecenyl and heptadecenyl. The straight-chain alkynyl having an odd number of carbon atoms includes those having 3 to 23, preferably 7 to 17 carbon atoms, such as propynyl, pentynyl, heptynyl, nonynyl, undecynyl, tridecynyl, pentadecynyl and heptadecynyl.

10 The number of unsaturated bonds in the alkenyl, alkynyl, straight-chain alkenyl having an odd number of carbon atoms and straight-chain alkynyl having an odd number of carbon atoms is not specifically restricted.

15 The lysophosphatidic acids to be used in the present invention may be any lysophosphatidic acids. The phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms to be used in the present invention include all such phosphatidic acids. The 20 straight-chain fatty acid having an even number of carbon atoms of the above fatty acid residues includes those having 2 to 24, preferably 8 to 18 carbon atoms, such as ethanoyl, butanoyl, hexanoyl, octanoyl, decanoyl, dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl, 25 eicosanoyl, docosanoyl, tetracosanoyl, 2-butenoyl, 3-butenoyl, 3-hexenoyl, 5-hexenoyl, hexadienoyl, octenoyl, decenoyl, dodecenoyl, tetradecenoyl, hexadecenoyl, octadecenoyl, butynoyl, hexynoyl, octynoyl, decynoyl, dodecynoyl, tetradecynoyl, hexadecynoyl, octadecynoyl and 30 tetradec-4-en-8-ynoyl. Of the above lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms, preferred are compounds represented by formula (I). Examples of the 35 lysophosphatidic acids are monoacetyl lysophosphatidic acid, monopropionyl lysophosphatidic acid, monobutanoyl

lysophosphatidic acid, monopentanoyl lysophosphatidic acid, monohexanoyl lysophosphatidic acid, monoheptanoyl lysophosphatidic acid, monoctanoyl lysophosphatidic acid, monononanoyl lysophosphatidic acid, monodecanoyl

5 lysophosphatidic acid, monoundecanoyl lysophosphatidic acid, monolauroyl lysophosphatidic acid, monotridecanoyl lysophosphatidic acid, monomyristoyl lysophosphatidic acid, monopentadecanoyl lysophosphatidic acid, monopalmitoyl lysophosphatidic acid, monolauryl lysophosphatidic acid and monooleoyl

10 lysophosphatidic acid. Examples of the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms are dioleoyl phosphatidic acid,

15 dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, dilauroyl phosphatidic acid, dioctanoyl phosphatidic acid, didecanoyl phosphatidic acid, distearoyl phosphatidic acid, arachidonoylstearyl phosphatidic acid, 1-oleoyl-2-acetyl phosphatidic acid, 1-lauroyl-2-acetyl phosphatidic acid, 1-myristoyl-2-acetyl phosphatidic acid, 1-palmitoyl-2-acetyl phosphatidic acid, 1-stearoyl-2-acetyl phosphatidic acid and 1-palmitoleyl-2-acetyl phosphatidic acid.

20 The lysophosphatidic acids to be employed in the hair-growing agent of the present invention comprising, as active ingredients, lysophosphatidic acid and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific inhibitors or pharmaceutically acceptable salts thereof, and tocopherol

25 30 are the same as the above-described lysophosphatidic acids.

35 The phosphatidic acids to be employed in the hair-growing agent of the present invention comprising, as active ingredients, phosphatidic acid and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific inhibitors or pharmaceutically acceptable salts thereof, and tocopherol

1000  
999  
898  
797  
696  
595  
494  
393  
292  
191  
090

include not only the above-described phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms, but also those wherein the fatty acid residue moiety consists of fatty acid residues having an odd number of carbon atoms, those wherein the fatty acid residue moiety consists of branched-chain fatty acid residues having an even number of carbon atoms, and those wherein the fatty acid residue moiety consists of the combination of the above different kinds of fatty acid residues. Examples of these phosphatidic acids include, in addition to the above-mentioned examples of phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms, dipropionyl phosphatidic acid, dipentanoyl phosphatidic acid, diheptanoyl phosphatidic acid, dinonanoyl phosphatidic acid, diundecanoyl phosphatidic acid, ditridecanoyl phosphatidic acid, dipentadecanoyl phosphatidic acid, diheptadecanoyl phosphatidic acid, di  $\alpha$ -methyloctadecanoyl phosphatidic acid, di  $\alpha$ -methylundecanoyl phosphatidic acid, di  $\beta$ -propylundecanoyl phosphatidic acid, di  $\alpha$ -methylstearoyl phosphatidic acid, di  $\alpha$ -methylpalmitoyl phosphatidic acid, di  $\alpha$ -methylnonanoyl phosphatidic acid, bis( $\gamma$ -dimethylnonanoyl) phosphatidic acid, bis( $\delta$ -ethyltridecanoyl) phosphatidic acid, 1-oleoyl-2-isobutyryl phosphatidic acid, 1-lauroyl-2-isobutyryl phosphatidic acid, 1-myristoyl-2-isobutyryl phosphatidic acid, 1-palmitoyl-2-isobutyryl phosphatidic acid, 1-stearoyl-2-isobutyryl phosphatidic acid, 1-palmitoleoyl-2-isobutyryl phosphatidic acid, 1-oleoyl-2-propionyl phosphatidic acid, 1-myristoyl-2-propionyl phosphatidic acid, 1-palmitoyl-2-propionyl phosphatidic acid, 1-stearoyl-2-propionyl phosphatidic acid and 1-palmitoleoyl-2-propionyl phosphatidic acid.

These phosphatidic acids can be obtained by

TENNESSEE - OIL


purification from egg yolk, soybean, etc. They can also be obtained as commercially available products or by chemical synthesis (for example, US 3423440).

Lysophosphatidic acids can be obtained by subjecting

5 phosphatidic acids obtained by purification from egg yolk, soybean, etc. to enzymatic treatment (hydrolysis with phospholipase A<sub>1</sub> or phospholipase A<sub>2</sub>) or by chemical synthesis (for example, US 3423440).

The proanthocyanidin used in the present invention

10 is a polymer composed of flavan-3-ol derivatives represented by formula (IV) :




15 (wherein R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represents a hydrogen atom or a hydroxyl group) or the like as constitutive units.

Examples of the flavan-3-ol derivatives include catechin, epicatechin, gallocatechin, epigallocatechin, 20 afzelechin, epiafzelechin and any optical isomers thereof. Proanthocyanidin composed of epicatechin or catechin as a constitutive unit is preferably used in the present invention.

The bonding mode of the flavan-3-ol derivatives represented by formula (IV) may be any mode. An example of a dimer composed of two flavan-3-ol derivatives is the one which has a bonding mode represented by formula (V) :

20110208-20254007



(wherein R<sup>3</sup> and R<sup>4</sup> have the same significances as defined above respectively, and R<sup>3a</sup> and R<sup>4a</sup> have the same significances as the above R<sup>3</sup> and R<sup>4</sup> respectively).  
 5 Trimmers and higher polymers may have a combination of these bonding modes which may be the same or different.

The proanthocyanidin to be used in the present invention may be any dimer or higher polymer of flavan-3-ol derivatives, and is preferably a 2- to 10-mer, more preferably a 2- to 5-mer, further preferably a dimer or trimer. Examples of the dimers of flavan-3-ol derivatives include epicatechin-catechin co-dimers such as epicatechin-(4 $\beta$ →8)-catechin, epicatechin dimers such as epicatechin-(4 $\beta$ →8)-epicatechin, and catechin dimers such as catechin-(4 $\alpha$ →8)-catechin. Examples of the trimers of flavan-3-ol derivatives include epicatechin trimers such as epicatechin-(4 $\beta$ →8)-epicatechin-(4 $\beta$ →8)-epicatechin, catechin trimers such as catechin-(4 $\alpha$ →8)-catechin-(4 $\alpha$ →8)-catechin, and epicatechin-catechin co-trimers such as epicatechin-(4 $\beta$ →8)-epicatechin-(4 $\beta$ →8)-catechin.  
 10  
 15  
 20

The proanthocyanidin to be used in the present invention also includes compounds wherein gallic acid or a sugar such as glucose or rhamnose is attached to the above proanthocyanidin.  
 25

Proanthocyanidin can be obtained by extraction and purification from various plants such as grape, apple,

barley, Japanese persimmon, coconut, cacao, pine, azuki bean and peanut belonging to the genera Vitis, Malus, Hordeum, Diospyros, Cocos, Theobroma, Pinus, Phaseolus, Arachis, and the like, or by chemical synthesis.

5 For instance, proanthocyanidin can be extracted and purified from plants according to the following known method.

Fruits, seeds, leaves, stalks, roots, rootstocks, etc. of the plants as starting materials are harvested at 10 a suitable stage and used, as such or usually after being subjected to drying such as air drying, as materials for extraction. Extraction of proanthocyanidin from dry plants can be carried out in a manner similar to known methods [Chemical & Pharmaceutical Bulletin, 3, 3218 (1990); *ibid.*, 15 40, 889-898 (1992)].

That is, the materials are ground or cut into fine pieces, followed by extraction with a solvent. Suitable solvents for extraction include hydrophilic or lipophilic solvents such as water, alcohols (e.g. ethanol, methanol 20 and isopropyl alcohol), ketones (e.g. acetone and methyl ethyl ketone) and esters (e.g. methyl acetate and ethyl acetate), which can be used alone or as a mixture. The temperature for extraction is usually 0 to 100°C, preferably 5 to 50°C. The time for extraction is about one 25 hour to 10 days, and the amount of the solvent is usually 1 to 30 times by weight, preferably 5 to 10 times by weight based on the dry material. Extraction is carried out by stirring or by dipping followed by standing, and is repeated twice or 3 times, as may be required.

30 The crude extract obtained in the above manner is filtered or centrifuged to remove the insoluble residue. Purification of proanthocyanidin from the thus treated extract or from juice or sap of the plants can be carried out by any known purification methods. It is preferred to 35 employ the two-phase solvent partitioning method, column chromatography, preparative high-performance liquid

2011.20.89264705

chromatography, etc. alone or in combination. The two-phase solvent partitioning methods include, for example, a method in which oil-soluble components and pigments are removed from the above extract by extraction with n-hexane,

5 petroleum ether, etc., and a method in which proanthocyanidin is collected from the extract into the solvent phase by partition between a solvent such as n-butanol or methyl ethyl ketone and water. Column chromatography includes a method using normal phase silica 10 gel and a method using reversed phase silica gel, adsorption column chromatography using as a carrier Diaion HP-20, Sepabeads SP-207 or the like, and gel filtration using as a carrier Sephadex LH-20 or the like. They are employed alone or in combination, if necessary repeatedly.

15 Preparative high-performance liquid chromatography includes a method using a reversed phase column packed with octadecyl silica or the like, and a method using a normal phase column packed with silica gel or the like.

Proanthocyanidin can be purified by removing water-soluble ionic substances such as salts, nonionic substances such as saccharides and polysaccharides, oils, 20 pigments, etc. from the above extract according to the above purification methods.

Grape-derived proanthocyanidin can be extracted and 25 purified according to the method described in *Acta Dermato Venereologica*, 78, 428-432 (1998) or a similar method.

Procyanidin B-1 [epicatechin-(4 $\beta$ →8)-catechin], procyanidin B-2 [epicatechin-(4 $\beta$ →8)-epicatechin], 30 procyanidin B-3 [catechin-(4 $\beta$ →8)-catechin] and procyanidin C-1 [epicatechin-(4 $\beta$ →8)-epicatechin-(4 $\beta$ →8)-epicatechin] can be extracted and purified according to the method described in *The Journal of Investigative Dermatology*, 112, 310-316 (1999) or a similar method.

Production of proanthocyanidin by chemical synthesis 35 can be carried out according to the method described in *Journal of Chemical Society, Perkin Transaction I*, 1535-

SEARCHED  
INDEXED  
SERIALIZED  
FILED

1543 (1983) in which a process of producing dimers of epicatechin or catechin is described, the method described in *Phytochemistry*, 25, 1209-1215 (1986) or similar methods.

When proanthocyanidin is used as an active

5 ingredient in the present invention, one or more kinds of proanthocyanidin may be used alone or as a mixture. It is preferred to use one or more members selected from the group consisting of grape-seed-derived proanthocyanidin, apple-derived proanthocyanidin, pine-derived  
10 proanthocyanidin, purified procyanidin oligomers, procyanidin B-1, procyanidin B-2, procyanidin B-3 and procyanidin C-1. Specifically it is preferred to use one or more members selected from the group consisting of procyanidin B-1, procyanidin B-2, procyanidin B-3 and procyanidin C-1.

As the protein kinase C-specific inhibitor in the present invention, any inhibitor that specifically inhibits protein kinase C can be used. It is preferred to use protein kinase inhibitors of which the ratio of the

20 50% protein kinase A (PKA) inhibition constant (hereinafter referred to as PKA-IC<sub>50</sub>) to the 50% protein kinase C (PKC) inhibition constant (hereinafter referred to as PKC-IC<sub>50</sub>) (the ratio is hereinafter referred to as PKA-IC<sub>50</sub>/PKC-IC<sub>50</sub>) is 3 or more, preferably 3 to 10<sup>9</sup>, more  
25 preferably 10 to 10<sup>9</sup>, when PKC-inhibiting activity and PKA-inhibiting activity are measured by the following methods for measuring PKC-inhibiting activity and PKA-inhibiting activity. Examples thereof are one or more members selected from the group consisting of calphostin C,  
30 hexadecylphosphocholine, palmitoyl-DL-carnitine, polymyxin B and pharmaceutically acceptable salts thereof.

Examples of the pharmaceutically acceptable salts are hydrochlorides, hydrobromides, sulfates, nitrates, formates, acetates, benzoates, maleates, fumarates, 35 succinates, tartrates, citrates, oxalates, methanesulfonates, toluenesulfonates, aspartates and

glutamates.

The methods for measuring PKC-inhibiting activity and PKA-inhibiting activity are described below.

5 (1) Method for Measuring PKC-inhibiting Activity

Measurement of PKC-inhibiting activity can be carried out in a manner similar to the method of Kikkawa, et al. [Journal of Biological Chemistry, 257, 13341 (1982)].

10 To 250  $\mu$ l of an aqueous solution comprising 2.5  $\mu$ mol of magnesium acetate, 50  $\mu$ g of histone Type IIIS (Sigma Chemical Co., Ltd.), 20  $\mu$ g of phosphatidylserine, 0.8  $\mu$ g of diolein, 25 nmol of calcium chloride, 5  $\mu$ g of a crude enzyme (partially purified from rat brain by the 15 method of Kikkawa, et al.) and 5  $\mu$ mol of Tris-HCl buffer (pH 7.5) is added the above aqueous solution containing a test compound (10  $\mu$ l), followed by incubation at 30°C for 3 minutes. After the incubation, 1.25 nmol of [ $\gamma$ - $^{32}$ P]ATP (5-10  $\times$  10<sup>3</sup> cpm/nmol) is added thereto, followed by 20 phosphorylation reaction at 30°C for 3 minutes. The reaction is terminated by addition of 25% trichloroacetic acid and the reaction mixture is filtered through a cellulose acetate membrane (pore size: 0.45  $\mu$ m, Toyo Filter Co., Ltd.) After the membrane is washed four times 25 with 5% trichloroacetic acid, the radioactivity remaining on the membrane is measured as a test compound value. Separately, the above procedure is carried out in the same manner without addition of the test compound and the radioactivity is measured as a control value.

30 The molar concentration of the test compound giving a test compound value which is 50% of the control value is regarded as the 50% PKC inhibition constant (PKC-IC<sub>50</sub>).

35 (2) Method for Measuring PKA-inhibiting Activity

Measurement of PKA-inhibiting activity can be carried out in a manner similar to the method of Kuo, et

207020-8925thD001

al. [Biochemistry, 64, 1349 (1969)].

To 250  $\mu$ l of an aqueous solution comprising 5  $\mu$ mol of Tris-HCl buffer (pH 6.8), 2.5  $\mu$ mol of magnesium acetate, 100  $\mu$ g of histone Type IIS (Sigma Chemical Co.,

5 Ltd.), 0.25 nmol of c-AMP and 200  $\mu$ g of a crude enzyme (partially purified from calf heart by the method of Kuo, et al.) is added the above aqueous solution containing a test compound (10  $\mu$ l), followed by incubation at 30°C for 3 minutes. After the incubation, 1.25 nmol of [ $\gamma$ - $^{32}$ P]ATP 10 (5-10  $\times 10^3$  cpm/nmol) is added thereto, followed by phosphorylation reaction at 30°C for 3 minutes. The reaction is terminated by addition of 25% trichloroacetic acid and the reaction mixture is filtered through a cellulose acetate membrane (pore size: 0.45  $\mu$ m, Toyo

15 Filter Co., Ltd.) After the membrane is washed four times with 5% trichloroacetic acid, the radioactivity remaining on the membrane is measured as a test compound value. Separately, the above procedure is carried out in the same manner without addition of the test compound and the 20 radioactivity is measured as a control value.

The molar concentration of the test compound giving a test compound value which is 50% of the control value is regarded as the 50% PKA inhibition constant (PKA-IC<sub>50</sub>).

The tocopherol to be used in the present invention includes natural ones that are commercially available, 25 synthetic ones, and derivatives such as acetic acid esters and nicotinic acid esters thereof. Examples thereof include dl- $\alpha$ -tocopherol, d- $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol acetate and dl- $\alpha$ -tocopherol

30 nicotinate.

The hair-growing agent of the present invention may be in any preparation form so long as it can contain lysophosphatidic acid, phosphatidic acid, or one or more members selected from the group consisting of

35 lysophosphatidic acids and phosphatidic acids, and one or more members selected from the group consisting of

TOP SECRET EDITION

proanthocyanidin, protein kinase C-specific inhibitors and pharmaceutically acceptable salts thereof, and tocopherol. For example, it can be used in the form of a liquid or solid hair-growing preparation containing a suitable

5 pharmaceutical vehicle.

Examples of the liquid or solid hair-growing preparations include liquid preparations such as hair liquid, hair tonic and hair lotion, and solid preparations such as ointment and hair cream. These preparations can

10 be produced by adding to a suitable vehicle

lysophosphatidic acid, phosphatidic acid, or one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids, and

15 proanthocyanidin, a protein kinase C-specific inhibitor or tocopherol, according to a conventional method.

The content of lysophosphatidic acid or phosphatidic acid in the hair-growing agent of the present invention widely varies depending upon the kind of lysophosphatidic acid or phosphatidic acid and the percutaneous

20 absorbability derived from physical properties, but it is usually, alone or as a mixture, 0.01 to 5.0 wt% (hereinafter referred to merely as %), preferably 0.01 to 3.0%, more preferably 0.1 to 1.0%. The content of

proanthocyanidin varies depending upon the purification

25 degree, but is usually 0.01 to 10.0%, preferably 0.1 to 5.0%, more preferably 0.3 to 2.0%. The content of a

protein kinase C-specific inhibitor widely varies

depending upon the inhibitory activity and the

percutaneous absorbability derived from physical

30 properties, but it is usually, alone or as a mixture, 0.00001 to 1%, preferably 0.0001 to 1%, more preferably

0.001 to 0.1%. The content of tocopherol is usually 0.01 to 2%, preferably 0.05 to 1%, more preferably 0.1 to 0.5%.

Preferred vehicles for liquid preparations are those

35 which are generally used in hair-growing agents such as purified water, ethyl alcohol and polyvalent alcohols. If

2021100  
15  
10  
5  
10  
15  
20  
25  
30  
35

necessary, additives may be added thereto.

Examples of the polyvalent alcohols are glycerol, 1,3-butylene glycol and propylene glycol.

Additives include surfactants, vitamins, anti-inflammatories, microbicides, hormones, crude drug extracts, tinctures, refrigerants, moisturizers, keratolytics, antioxidants, sequestering agents and perfumes.

Examples of the surfactants are polyoxyethylene (60) hardened castor oil, polyoxyethylene (8) oleyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (10) monooleate, polyoxyethylene (30) glyceryl monostearate, sorbitan monostearate, polyoxyethylene (30) glyceryl monostearate, polyoxyethylene (20) sorbitan monooleate, sucrose fatty acid esters, hexaglycerin monooleate, hexaglycerin monolaurate, polyoxyethylene reduced lanolin, polyoxyethylene (20) lanolin alcohol, polyoxyethylene (25) glyceryl pyroglutamate isostearate, and N-acetylglutamine isostearyl ester.

Examples of the vitamins are benzyl nicotinate, nicotinamide, D-pantothenyl alcohol, pantothenyl ethyl ether, biotin, pyridoxine hydrochloride and riboflavin.

Examples of the anti-inflammatory agents are dipotassium glycyrrhizinate,  $\beta$ -glycyrrhetic acid, allantoin, diphenhydramine hydrochloride, guaiazulene and 1-menthol.

Examples of the microbicides are trichlorohydroxydiphenyl ether, hinokitiol, triclosan, chlorohexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, zinc pyrithione, benzalkonium chloride, photosensitizing dye No. 301 and sodium mononitroguaiacol.

Examples of the hormones are ethynodiol, estrone and estradiol.

Examples of the crude drug extracts are extract of Swertia japonica Makino, garlic extract, ginseng extract,

20720-39269007

aloe extract and cinchona extract.

Examples of the tinctures are capsicum tincture, ginger tincture and cantharis tincture.

Examples of the refrigerants are capsicum tincture, 5 1-menthol and camphor.

Examples of the moisturizers are L-pyrrolidonecarboxylic acid, sodium hyaluronate, chondroitin sulfate, plant worm extract and saffron extract.

10 Examples of the keratolytics are resorcin, salicylic acid and lactic acid.

Examples of the antioxidants are butylhydroxyanisole, isopropyl gallate, propyl gallate and erythorbic acid.

15 Examples of the sequestering agents are ethylenediamine tetraacetate and salts thereof.

Examples of the perfumes are natural perfumes such as orange oil, lemon oil, bergamot oil, lime oil, lemongrass oil and lavender oil, and synthetic perfumes such as menthol, rose oxide, linalool, citral and linalyl acetate.

20 When the above liquid preparations are used as spray, they can be used in combination with combustible gas, incombustible gas, or the like. Examples of the combustible gas are LPG (a liquefied petroleum gas) and 25 dimethyl ether, and examples of the incombustible gas are a nitrogen gas and a carbon dioxide gas.

Vehicles for solid preparations include Vaseline, solid paraffin, vegetable oils, mineral oils, lanolin, wax and macrogol. Further, the above additives, emulsifiers 30 such as lecithin, and lower alcohols such as ethyl alcohol and isopropyl alcohol may be added thereto, if necessary.

The dose of the hair-growing agent of the present invention varies depending upon the age, the body weight, the symptom of the disease, the therapeutic effect, the 35 mode of administration, the time of treatment or the like. The agent is percutaneously administered in an amount of

COPYRIGHTED MATERIAL

0.1 to 250 mg, preferably 1 to 100 mg in terms of lysophosphatidic acid or phosphatidic acid per adult once to several times per day.

5 Certain embodiments of the present invention are illustrated in the following examples.

Best Modes for Carrying out the Invention

Example 1 Preparation of Compositions 1 and 2

Monopalmitoyl lysophosphatidic acid	0.3%
(Funakoshi Co., Ltd.)	
Ethyl alcohol	70%
1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate	0.25%
isostearate	

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 1.

20 Composition 2 was prepared in the same manner as above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

Example 2 Preparation of Compositions 3 and 4

Monopalmitoyl lysophosphatidic acid	0.3%
(Funakoshi Co., Ltd.)	
Grape-derived proanthocyanidin	3%
Ethyl alcohol	70%
1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate	0.25%
isostearate	

35 Grape-derived proanthocyanidin was produced according to the method described in *Acta Dermato Venereologica*, 78, 428-432 (1998) or a similar method.

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 3.

Composition 4 was prepared in the same manner as 5 above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

Example 3 Preparation of Compositions 5 and 6

Monopalmitoyl lysophosphatidic acid	0.3%
10 (Funakoshi Co., Ltd.)	
Procyanidin B-2	1%
Ethyl alcohol	70%
1,3-Butylene glycol	3%
15 N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate	0.25%
isostearate	

Procyanidin B-2 was produced according to the method described in The Journal of Investigative Dermatology, 112, 20 310-316 (1999) or a similar method.

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 5.

Composition 6 was prepared in the same manner as 25 above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

Example 4 Preparation of Compositions 7 and 8

Monopalmitoyl lysophosphatidic acid	0.3%
30 (Funakoshi Co., Ltd.)	
Procyanidin C-1	1%
Ethyl alcohol	70%
1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
35 Polyoxyethylene (25) glyceryl pyroglutamate	0.25%
isostearate	

Procyanidin C-1 was produced according to the method described in The Journal of Investigative Dermatology, 112, 310-316 (1999) or a similar method.

5 To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 7.

Composition 8 was prepared in the same manner as above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

10

Example 5 Preparation of Compositions 9 and 10

Monopalmitoyl lysophosphatidic acid (Funakoshi Co., Ltd.)	0.3%
Calphostin C (Kyowa Hakko Kogyo Co., Ltd.)	0.03%
Ethyl alcohol	90%
1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%

20

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 9.

Composition 10 was prepared in the same manner as above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

Example 6 Preparation of Compositions 11 and 12

Monopalmitoyl lysophosphatidic acid (Funakoshi Co., Ltd.)	0.3%
Hexadecylphosphocholine (Sigma Chemical Co., Ltd.)	0.3%
Ethyl alcohol	70%
1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 11.

Composition 12 was prepared in the same manner as above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

Example 7 Preparation of Compositions 13 and 14

10	Monopalmitoyl lysophosphatidic acid (Funakoshi Co., Ltd.)	0.3%
15	dl- $\alpha$ -Tocopherol (Eisai Co., Ltd.)	1%
	Ethyl alcohol	70%
	1,3-Butylene glycol	3%
20	N-Acetylglutamine isostearyl ester	0.25%
25	Polyoxyethylene (25) glycercyl pyroglutamate isostearate	0.25%

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 13.

Composition 14 was prepared in the same manner as above except that purified water was used instead of monopalmitoyl lysophosphatidic acid.

Example 8 Preparation of Compositions 15 and 16

25	Dioleoyl phosphatidic acid (Sigma Chemical Co., Ltd.)	0.4%
	Ethyl alcohol	70%
	1,3-Butylene glycol	3%
	N-Acetylglutamine isostearyl ester	0.25%
30	Polyoxyethylene (25) glycercyl pyroglutamate isostearate	0.25%

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 15.

Composition 16 was prepared in the same manner as

TOP SECRET - DRAFT

above except that purified water was used instead of dioleoyl phosphatidic acid.

Example 9 Preparation of Compositions 17 and 18

5	Dioleoyl phosphatidic acid (Sigma Chemical Co., Ltd.)	1%
	Procyanidin B-2	1%
	Ethyl alcohol	70%
	1,3-Butylene glycol	3%
	N-Acetylglutamine isostearyl ester	0.25%
10	Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%

15 Procyanidin B-2 was produced according to the method described in The Journal of Investigative Dermatology, 112, 310-316 (1999).

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 17.

20 Composition 18 was prepared in the same manner as above except that purified water was used instead of dioleoyl phosphatidic acid.

Example 10 Preparation of Compositions 19 and 20

25	Dioleoyl phosphatidic acid (Sigma Chemical Co., Ltd.)	1%
	Procyanidin C-1	1%
	Ethyl alcohol	70%
	1,3-Butylene glycol	3%
	N-Acetylglutamine isostearyl ester	0.25%
	Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%
30		

310-316 (1999).  
35 Procyanidin C-1 was produced according to the method described in The Journal of Investigative Dermatology, 112,

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with

stirring to prepare composition 19.

Composition 20 was prepared in the same manner as above except that purified water was used instead of dioleoyl phosphatidic acid.

5

Example 11 Preparation of Compositions 21 and 22

Dioleoyl phosphatidic acid (Sigma Chemical Co., Ltd.)	1%
Hexadecylphosphocholine (Sigma Chemical Co., Ltd.)	0.3%
Ethyl alcohol	70%
10 1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%

15

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 21.

Composition 22 was prepared in the same manner as above except that purified water was used instead of dioleoyl phosphatidic acid.

20

Example 12 Preparation of Compositions 23 and 24

Dioleoyl phosphatidic acid (Sigma Chemical Co., Ltd.)	1%
dl- $\alpha$ -Tocopherol (Eisai Co., Ltd.)	1%
25 Ethyl alcohol	70%
1,3-Butylene glycol	3%
N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%

30

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 23.

Composition 24 was prepared in the same manner as above except that purified water was used instead of dioleoyl phosphatidic acid.

35

Example 13 Preparation of Composition 25

Dilauroyl phosphatidic acid (Funakoshi Co., Ltd.)	0.2%
Ethyl alcohol	70%
1,3-Butylene glycol	3%
5 N-Acetylglutamine isostearyl ester	0.25%
Polyoxyethylene (25) glyceryl pyroglutamate isostearate	0.25%

To the above mixture was added purified water to make up to 100%. The mixture was made homogeneous with stirring to prepare composition 25.

Reference Example 1 Measurement of PKC-IC<sub>50</sub> and PKA-IC<sub>50</sub>

PKC-IC<sub>50</sub> and PKA-IC<sub>50</sub> were obtained on calphostin C, hexadecylphosphocholine, palmitoyl-DL-carnitine and polymyxin B by measuring their PKC- and PKA-inhibiting activities according to the above-described methods for measuring PKC- and PKA-inhibiting activities.

The results are shown in Table 1.

Table 1

Test Compound	PKC-IC <sub>50</sub> ( $\mu$ M)	PKA-IC <sub>50</sub> ( $\mu$ M)	PKA-IC <sub>50</sub> / PKC-IC <sub>50</sub>
Calphostin C	0.05	>50	>1000
Hexadecyl- phosphocholine	94	>1000	>10.6
Palmitoyl-DL- carnitine	230	>1000	>4.3
Polymyxin B	2.6	>1000	>384

The activity of the hair-growing agent of the present invention is shown in detail by the following test examples.

Test Example 1 Cell Growth-Promoting Effect on Cultured Mouse Hair Follicle Epithelial Cells

Hair follicle epithelial cells were separated and cultured according to a modification of the method of Tanigaki, et al. [Archives of Dermatological Research, 284, 290-296 (1992)].

5 The skin on the back of a 4-days-old C3H mouse (Charles River Japan, Inc.) was cut off and treated with MEM (Eagle's Minimum Essential Medium) containing 500 units/ml Dispase (Godo Shusei Co., Ltd.) and 5% fetal calf serum (FCS) at 4°C for 16 hours.

10 Then, the epidermis was stripped from the skin section, and the obtained dermis layer was treated with DMEM (Dulbecco's modified Eagle Medium) containing 0.25% Collagenase N-2 (Nitta Gelatin Co., Ltd.) and 10% FCS at 37°C for one hour to obtain a dermis suspension. The 15 dermis suspension was filtered through a 212- $\mu$ m nylon mesh (Nippon Rikagaku Kikai Co., Ltd.) and the filtrate was centrifuged at 1000 rpm for 5 minutes to obtain pellets containing hair follicle tissue. To the pellets was added calcium/magnesium-free PBS (Dulbecco's 20 Phosphate-Buffered Saline) and the pellets were suspended therein using a pipette. The resulting suspension was allowed to stand for 15 minutes to precipitate hair tissue. The same procedure as above (addition of 25 calcium/magnesium-free PBS, suspending by use of a pipette, and precipitation by allowing suspension to stand for 15 minutes) was repeated three times using the obtained hair tissue.

30 Then, the hair tissue was treated with a solution containing 0.1% ethylenediaminetetraacetic acid (EDTA) and 0.25% trypsin (Gibco) at 37°C for 5 minutes. To the resulting mixture was added DMEM containing 10% FCS to 35 prepare a hair tissue cell suspension having a density of  $3 \times 10^5$  cells/ml. The hair tissue cell suspension was put into wells of a 24-well collagen-coated plate (Iwaki Glass Co., Ltd.) in an amount of 1 ml/well, followed by culturing in 5% CO<sub>2</sub> at 37°C for 24 hours.

After the culturing, the medium was replaced by a medium prepared by adding to MCDB153 medium (Kyokuto Pharmaceutical Ind. Co., Ltd.) DMSO containing 5 mg/l bovine insulin (Sigma Chemical Co., Ltd.); 5  $\mu$ g/l mouse epidermal growth factor (EGF) (Takara Shuzo Co., Ltd.); 40 mg/l bovine pituitary extract (Kyokuto Pharmaceutical Ind. Co., Ltd.); 10 mg/l human transferrin (Sigma Chemical Co., Ltd.); 0.4 mg/l hydrocortisone (Sigma Chemical Co., Ltd.); 0.63  $\mu$ g/l progesterone (Collaborative Research Co.); 14 mg/l O-phosphoethanolamine (Sigma Chemical Co., Ltd.); 6.1 mg/l ethanolamine (Sigma Chemical Co., Ltd.); 50 U/ml penicillin (Wako Pure Chemical Industries, Ltd.); 50  $\mu$ g/ml streptomycin (Wako Pure Chemical Industries, Ltd.); monooleoyl lysophosphatidic acid, dioleoyl phosphatidic acid (Sigma Chemical Co., Ltd.), didecanoyl phosphatidic acid (Sigma Chemical Co., Ltd.), dimyristoyl phosphatidic acid (Funakoshi Co., Ltd.), dipalmitoyl phosphatidic acid (Wako Pure Chemical Industries, Ltd.), dilauroyl phosphatidic acid (Funakoshi Co., Ltd.) or egg yolk-derived phosphatidic acid (Sigma Chemical Co., Ltd.); and/or proanthocyanidin, a protein kinase C-specific inhibitor or tocopherol (added in an amount of 1/100 by volume), followed by further culturing in 5% CO<sub>2</sub> at 37°C for 5 days. During the culturing, the medium was replaced with a fresh one every other day.

As a control, the cells were cultured in the same medium as above except that DMSO alone was added in an amount of 1/100 by volume in place of DMSO containing lysophosphatidic acid or phosphatidic acid, and/or proanthocyanidin, a protein kinase C-specific inhibitor or tocopherol.

The degree of cell growth was measured according to the method using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] [Experimental Medicine (extra number), Bio Manual UP Series, Experimental Method of Cell Culture for Molecular Biological Studies, p. 89-92,

Yodosha (1995)].

To each well of the 24-well microplate (2 cm<sup>2</sup>/well) was added a PBS solution of MTT (5 mg/ml) in an amount of 1/10 by volume based on 1 ml of the culture. The plate was shaken to make the mixture homogeneous, followed by culturing in 5% CO<sub>2</sub> at 37°C for 4 hours. Four hours later, the culture was sucked and 1 ml of a 0.04 mol/l solution of HCl in isopropyl alcohol was added to each well to completely dissolve formazan formed in the wells.

The degree of cell growth was determined by measuring the absorbance at 570 nm based on that at 650 nm as a control.

The cell growth-promoting activity of the compounds used in the present invention is shown in Table 2.

Table 2 (1) Cell growth-promoting activity of lysophosphatidic acid

Active ingredient	Relative cell growth rate based on the control as 100
Procyanidin B-2 (30 μmol/l)	260
Procyanidin B-2 (30 μmol/l) + monooleoyl lysophosphatidic acid (3 μmol/l)	327
Calphostin C (3 μmol/l)	180
Calphostin C (3 μmol/l) + monooleoyl lysophosphatidic acid (3 μmol/l)	272
dl-α-Tocopherol (30 μmol/l)	150
dl-α-Tocopherol (30 μmol/l) + monooleoyl lysophosphatidic acid (3 μmol/l)	240
Monooleoyl lysophosphatidic acid (3 μmol/l)	200

Table 2 (2) Cell growth-promoting activity of phosphatidic acids

Active ingredient	Relative cell growth rate based on the control as 100
Procyanoindin B-2 (10 $\mu\text{mol/l}$ )	251
Procyanoindin B-2 (10 $\mu\text{mol/l}$ ) + dioleoyl phosphatidic acid (10 $\mu\text{mol/l}$ )	346
Calphostin C (0.01 $\mu\text{mol/l}$ )	172
Calphostin C (0.01 $\mu\text{mol/l}$ ) + phosphatidic acids derived from egg yolk lecithin (20 $\mu\text{mol/l}$ )	314
dl- $\alpha$ -Tocopherol (30 $\mu\text{mol/l}$ )	199
dl- $\alpha$ -Tocopherol (30 $\mu\text{mol/l}$ ) + phosphatidic acids derived from egg yolk lecithin (20 $\mu\text{mol/l}$ )	341
Dilauroyl phosphatidic acid (10 $\mu\text{mol/l}$ )	379
Dimyristoyl phosphatidic acid (10 $\mu\text{mol/l}$ )	361
Dipalmitoyl phosphatidic acid (20 $\mu\text{mol/l}$ )	314
Dioleoyl phosphatidic acid (10 $\mu\text{mol/l}$ )	255
Didecanooyl phosphatidic acid (1 $\mu\text{mol/l}$ )	168
Phosphatidic acids derived from egg yolk lecithin (20 $\mu\text{mol/l}$ )	273

As shown in Table 2, the hair-growing agent of the present invention exhibited a significant growth-promoting activity on mouse hair follicle epithelial cells.

Test Example 2 Effect on Hair Growth of Mouse

A test of the effect on hair growth of mice was carried out referring to the method of Ogawa, et al. [The Journal of Dermatology, 10, 45-54, (1983)].

Nine-weeks-old male C3H/HeSlc mice whose hair cycle was in the telogen were divided into groups each consisting of 4 or 5 mice. Hair on the back of each mouse was shaven using electric hair clippers and an electric shaver. Then, the compositions prepared in Examples 1-14

were applied on the shaven part in an amount of 200  $\mu$ l once per day. To the mice of control groups were applied compositions 2 and 16 respectively in the same manner.

On the 18th day after the start of the test, the skin on the back of each mouse was cut off and photographed. Using an image processor (Avionics Co., Spicca II), the percentage of the hair-grown area to the total area of the skin on the back was calculated. The rate of the increased hair-grown area (%) was obtained by subtracting the hair-growing rate of the control group from the hair-growing rate of the test group.

The results are shown in Table 3.

Table 3 (1) Growth-promoting effect of lysophosphatidic acid on mouse hair follicle

Composition	Rate of increased hair-grown area (%)
2 (Control group)	0
1	35
3	60
4	45
5	64
6	51
7	67
8	57
9	68
10	60
11	73
12	63
13	60
14	45

Table 3 (2) Growth-promoting effect of phosphatidic acids  
on mouse hair follicle

Composition	Rate of increased hair-grown area (%)
16 (Control group)	0
15	44
17	51
18	40
19	55
20	44
21	58
22	46
23	52
24	39
25	41

As shown in Table 3, the hair-growing agents comprising lysophosphatidic acid or phosphatidic acid of the present invention exhibited a significant growth-promoting effect on mouse hair follicles. The growth-promoting effect of proanthocyanidin, protein kinase C-specific inhibitors and tocopherol on hair follicles was reinforced by using them together with the lysophosphatidic acid.

Industrial Applicability

The present invention provides a safe hair-growing agent having an excellent scalp hair-growing effect which comprises, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

## CLAIMS


1. A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

10 2. The hair-growing agent according to Claim 1, which does not substantially comprise minoxidil.

15 3. The hair-growing agent according to Claim 1 or 2, wherein the content of one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms is 0.01 to 5.0%.


20 4. The hair-growing agent according to Claim 1 or 2, wherein the content of one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms is 0.01 to 1.0%.

25 5. The hair-growing agent according to any of Claims 1 to 4, wherein the lysophosphatidic acids are compounds represented by formula (I):



(wherein R<sup>1</sup> represents alkyl, alkenyl or alkynyl).


6. The hair-growing agent according to any of claims 1 to 4, wherein the lysophosphatidic acids are 5 compounds represented by formula (II):



(wherein R<sup>2</sup> has the same significance as the above R<sup>1</sup>).

10

7. The hair-growing agent according to any of Claims 1 to 4, wherein the phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms 15 are compounds represented by formula (III):



(wherein R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, 20 each represents straight-chain alkyl having an odd number of carbon atoms, straight-chain alkenyl having an odd number of carbon atoms, or straight-chain alkynyl having an odd number of carbon atoms).

25

8. A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids and phosphatidic acids, and one or more members selected from the group consisting of proanthocyanidin, protein kinase C-specific

inhibitors or pharmaceutically acceptable salts thereof, and tocopherol.

9. A hair-growing agent comprising, as active  
5 ingredients, one or more members selected from the group  
consisting of lysophosphatidic acids and phosphatidic  
acids, and proanthocyanidin.

10. The hair-growing agent according to Claim 8 or  
10 9, wherein the proanthocyanidin is one or more members  
selected from the group consisting of procyanidin B-1,  
procyanidin B-2, procyanidin B-3 and procyanidin C-1.

11. The hair-growing agent according to Claim 9 or  
15 10, further comprising a protein kinase C-specific  
inhibitor or a pharmaceutically acceptable salt thereof.

12. A hair-growing agent comprising, as active  
20 ingredients, one or more members selected from the group  
consisting of lysophosphatidic acids and phosphatidic  
acids, and a protein kinase C-specific inhibitor or a  
pharmaceutically acceptable salt thereof.

13. The hair-growing agent according to Claim 8, 11  
25 or 12, wherein the protein kinase C-specific inhibitor is  
one or more members selected from the group consisting of  
calphostin C, hexadecylphosphocholine, palmitoyl-DL-  
carnitine and polymyxin B.

30 14. The hair-growing agent according to any of  
Claims 9 to 13, further comprising tocopherol.

15. A hair-growing agent comprising, as active  
35 ingredients, one or more members selected from the group  
consisting of lysophosphatidic acids and phosphatidic  
acids, and tocopherol.

16. The hair-growing agent according to Claim 8, 14  
or 15, wherein the tocopherol is one or more members  
selected from the group consisting of dl- $\alpha$ -tocopherol, d-  
 $\alpha$ -tocopherol, dl- $\alpha$ -tocopherol acetate, d- $\alpha$ -tocopherol  
acetate and dl- $\alpha$ -tocopherol nicotinate.

17. The hair-growing agent according to any of  
Claims 8 to 16, wherein the phosphatidic acids are the  
phosphatidic acids according to Claim 1.

10 18. The hair-growing agent according to Claim 17,  
wherein the phosphatidic acids are the phosphatidic acids  
according to Claim 7.

15 19. The hair-growing agent according to any of  
Claim 8 to 16, wherein the lysophosphatidic acids are the  
lysophosphatidic acids according to Claim 5 or 6.

20 20. The hair-growing agent according to Claims 8 to  
19, which does not substantially comprise minoxidil.

25 21. The hair-growing agent according to any of  
Claims 8 to 20, wherein the content of one or more members  
selected from the group consisting of lysophosphatidic  
acids and phosphatidic acids is 0.01 to 5.0%.

30 22. The hair-growing agent according to any of  
Claims 8 to 20, wherein the content of one or more members  
selected from the group consisting of lysophosphatidic  
acids and phosphatidic acids is 0.01 to 1.0%.

100-99887-2  
100-99887-2  
100-99887-2  
100-99887-2

## ABSTRACT

A hair-growing agent comprising, as active ingredients, one or more members selected from the group 5 consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

201120-8926400

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT COOPERATION TREATY APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled HAIR-GROWING AGENT

the specification of which was filed as PCT International Application No. PCT/JP00/05542 on 18/08/00 and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Country	Application No.	Filed (Day/Mo/Yr.)	Priority Claimed (Yes/No)
JP	231144/99	18/08/99	YES
JP	137711/00	10/05/00	YES

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number:

FITZPATRICK, CELLA, HARPER & SCINTO  
Customer Number: 05514

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT COOPERATION TREATY APPLICATION  
(Page 2)

1-00 Full Name of Sole or First Inventor Tomoya Takahashi

Inventor's signature Tomoya Takahashi

Date January 22, 2002 Citizen/Subject of Japan

Residence Tsuchiura-shi, Ibaraki, Japan JPX

Post Office Address c/o Tsukuba Research Laboratories, KYOWA HAKKO KOGYO CO., LTD.,  
2, Miyukigaoka, Tsukuba-shi, Ibaraki 305-0841 Japan

2-00 Full Name of Second Joint Inventor, if any Ayako Kamimura

Second Inventor's signature Ayako Kamimura

Date January 22, 2002 Citizen/Subject of Japan

Residence Tsukuba-shi, Ibaraki, Japan JPX

Post Office Address c/o Tsukuba Research Laboratories, KYOWA HAKKO KOGYO CO., LTD.,  
2, Miyukigaoka, Tsukuba-shi, Ibaraki 305-0841 Japan

3-00 Full Name of Third Joint Inventor, if any Takako Matsuoka

Third Inventor's signature Takako Matsuoka

Date January 17, 2002 Citizen/Subject of Japan

Residence Same as Post Office Address

Post Office Address 2273-1, Ikuwa-cho, Yokkaichi-shi, Mie 512-0911 Japan JPX

4-00 Full Name of Fourth Joint Inventor, if any

Fourth Inventor's signature

Date \_\_\_\_\_ Citizen/Subject of \_\_\_\_\_

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

5-00 Full Name of Fifth Joint Inventor, if any

Fifth Inventor's signature

Date \_\_\_\_\_ Citizen/Subject of \_\_\_\_\_

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

6-00 Full Name of Sixth Joint Inventor, if any

Sixth Inventor's signature

Date \_\_\_\_\_ Citizen/Subject of \_\_\_\_\_

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_